Antiretroviral therapy (ART) 
INTRODUCTION
HIV is a global public health problem. In 2016, more than a million people died from HIV-associated causes around the world. The aim of antiretroviral therapy is to suppress viral replication, strengthen the individual's immune system, and regain the capacity to resist infections. In accordance to World Health Organization (WHO) recommendations, antiretroviral therapy (ART) should be initiated in all people living with HIV, regardless of WHO clinical stage and CD4 + T-cell count (Anonymous, 2016a) . Unfortunately, failure is not a rare outcome of ART, which remains the subject of empirical studies (Boettiger et al., 2014; Patrikar et al., 2017) .
ART failure is associated with a variety of factors: poor adherence to medication, missed visits, a higher baseline viral load, a lower baseline CD4 + T-cell count, a low absolute neutrophil count, low BMI, and opportunistic infections (Lucas et al., 1999; Lundgren et al., 2002; Robbins et al., 2007; Patrikar et al., 2017) . Treatment failure can be assessed through monitoring of viral load, CD4 + T-cell count, and a new or recurrent clinical event. In accordance with WHO recommendations (Anonymous, 2016a) , viral load monitoring is preferred for confirming treatment failure. However, based on a negative relationship between viral load and CD4 + T-cell count (Pantaleo and Fauci, 1996) , al., 2009; Odafe et al., 2012; Montarroyos et al., 2014; Gezie et al., 2017) .
Studies have also shown that a response to ART is related to allelic variants of different genes (Haas et al., 2005; Zhu et al., 2005) . One of the groups of these genes is the Human Leukocyte Antigens (HLA), which are essential in the regulation of immune response. Previous studies demonstrated that HLA Class I and Class II alleles affect susceptibility to HIV infection and development time of AIDS (Saah et al., 1998; Keet et al., 1999) , viral control in ART-naive patients (Jugl et al., 2011; Ranasinghe et al., 2013) , and adverse reactions during ART (Mallal et al., 2002; Pavlos et al., 2012) . In ART-naive patients, The HLA-DRB1*03:01 allele (significantly) and HLA-DRB1*04:04, 01:01, 15:01, and 08:01 alleles (with marginal significance) were shown to be associated with high viremia (Ranasinghe et al., 2013) . At the same time, information about effect of HLA genes on ART effectiveness is limited. In early-treated patients, the HLA-DRB1*13/HLA-DQB1*06 haplotype had a protective effect on virological and immunological responses (Malhotra et al., 2001) .
The goal of the present study was to determine the effect of HLA Class II alleles on response to long-term ART by estimating change in CD4 + T cells in relation to viral load. We expected that alleles associated with high viremia in ARTnaive patients can negatively affect the progress in ART (Ranasinghe et al., 2013) , while protective alleles can positively affect ART (Malhotra et al., 2001) .
MATERIALS AND METHODS
The study was retrospective, approved by the Central Medical Ethics Committee, Rîga, Latvia. The sample included 69 patients (17 females and 52 males) aged 20 to 50 (mean age was 32.68, SD = 8.38) with HIV-1 infection, who were undergoing ART in the Latvian Centre of Infectious Diseases (currently Latvian Centre of Infectious Diseases of Rîga Eastern Clinical University Hospital) in the period from 1998 till 2012. Inclusion criteria were: confirmed HIV-1 infection, received ART in accordance with recommendations, and monitoring of CD4 + T-cell count and viral load. The diagnosis of HIV-1 infection was confirmed by detection of specific antibodies and HIV-1 antigen (ELISA) and specific antibodies to HIV-1, using the Immunoblot and Western blot methods.
The median period of observations in the study was 5.7 years (from 4 to 7 years). All patients received ART in accordance to national recommendations: two nucleoside reverse transcriptase inhibitors (NRTI) combined with one protease inhibitor (PI) or one non-nucleoside reverse transcriptase inhibitor (NNRTI).
Information about patient age, sex, treatment regiment, and compliance was collected from medical documentation. In addition, the documentation included data on viral load and CD4 + T-cell count at the beginning and end of the observation period. Both investigations were performed at the Latvian Centre of Infectious Diseases. Viral load testing was performed by the polymerase chain reaction. CD4 + T-cell count was determined by flow cytometry. The statistical analysis was performed using IBM SPSS Statistics for Windows, Version 22.0. Normality of distribution was assessed using the Shapiro-Wilk and KolmogorovSmirnov tests with Lilliefors significance correction. Significance of differences in values at two difference times was determined using the Wilcoxon test. The relationship between parameters was estimated using Pearson productmoment correlation coefficient. A multiple hierarchical linear regression analysis combined a standard regression for a change in CD4 + T-cell count predicted by a change in the viral load and a statistical regression for the assessment of alleles as additional predictors.
RESULTS
A quantitative analysis of the alleles was performed. Table  1 summarises the observed allele frequencies. A multiple hierarchical linear regression was applied to determine predictors of a change in the CD4 + T-cell count.
The regression model combined a standard regression for log viral load at the first step and a statistical regression for HLA Class II alleles at the next steps. In addition, age, sex, and time length between first and second time points were controlled during the analysis. Step 1: F (4, 64) = 3.68, p < 0.01; R 2 = 0.19; adjusted R 2 = 0.14. Step 3: F (6, 62) = 5.69, p < 0.001; R 2 = 0.36; adjusted R 2 = 0.29; DR 2 = 0.06. The following analysis demonstrated that haplotypes associated with revealed alleles are rarely presented. HLA-DRB1*04/HLA-DQA1*01:04 and HLA-DRB1*06/HLA-DQB1*06:01 were presented once. The haplotype HLA-DQA1*01:02/HLA-DQB106:01 was observed two times, and HLA-DRB1*04/HLA-DQB1*03:02 was identified three times. Adding them to the analysis demonstrated no significant change in the predicted model.
Constant

DISCUSSION
In addition to the well-known association between CD4 + T-cell count and HIV-1 viral load (Pantaleo and Fauci, 1996) , the present study demonstrated effect of HLA Class II alleles on the observed change in CD4 + T-cell count.
Among the alleles under investigation, HLA-DRB1*04 and HLA-DQB1*06:01 demonstrated statistically significant association with decreasing CD4 + T-cell count over the ART period of 5 to 7 years. Taking into account that CD4 + T-cell count is one of the key indicators of the HIV disease progression (Mellors et al., 1997; Langford et al., 2007) , we conclude that these alleles had a negative impact on ART in the present cohort.
The observed negative impact of the HLA-DRB1*04 genotype on the course of HIV-1 infection during ART is in accordance with previous studies (Saah et al., 1998; Ranasinghe et al., 2013) , which showed that the HLA-DRB1*04 genotype was a HLA marker with adverse effect in HIV-1 patients.
The present study showed also negative effect of the HLA-DQB1*06:01 allele on the HIV-1 course during long-term ART. This is in contrast with a study (Malhotra et al., 2001) that demonstrated a protective effect of HLA-DQB1*06:01 allele within the HLA-DRB1*13/HLA-DQB1*06 haplotype. Patients who inherited this haplotype had a greater likelihood of effectively controlling HIV-1 replication during 18 month-long ART (Malhotra et al., 2001) . A possible explanation of this effect can be associated with the time interval of therapy and the cohort involved in our study.
It should be noted that the role of HLA Class II alleles in therapy was investigated for different pathologies. In patients with multiple sclerosis receiving long-term interferon beta therapy, 04:01 and 04:08 alleles of HLA-DRB1*04 allelic group were associated with the production of antibodies against interferon beta therapy leading to a less effective interferon beta treatment (Buck et al., 2011) . In addition, the HLA-DRB1*04 allelic group had a role in predisposition to the most severe form of rheumatoid arthritis (Zanelli et al., 2002; Balandraud et al., 2013) and more rapid disease progression (Kapitány et al., 2008) . HLA-DRB1*04 alleles, particularly homozygosity for HLA-DRB1*04, were univariate predictors of radiographic progression (Goronzy et al., 2004) . Therefore, the HLA-DRB1*04 allelic group is a risk marker for a variety of pathologies. This conclusion indicates the direction for the further study on multiple immunological effects of this allelic group in therapy, including the level of CD4 + T-cell change.
It should be noted that the present study had some limitations. The number of patients under observation was relatively low, which was due to socioeconomic difficulties limiting inclusion and following patients during the study. However, it allowed and provide an initial statistical assessment. Taking into account the broad temporal interval of observations in this study, a more coherent sample should be preferred for the further investigation of long-time ART. A stronger control of virological, immunological, and clinical markers of treatment failure is needed for a more detailed description of change dynamics.
It can be concluded that, as host genetic factors, HLA Class II alleles can affect long-time ART and disease progression. Our study demonstrated that HLA-DRB1*04 and HLA-DQB1*06:01 alleles are risk markers in the Latvian cohort of HIV-1 patients undergoing long-time ART. Information regarding patient's HLA Class II genotype might be helpful to guide ART in patients with HIV-1 infection.
